复杂核型而非其他细胞遗传学异常与核磷蛋白1突变急性髓系白血病患者移植后生存较差相关:欧洲血液与骨髓移植学会急性白血病工作组研究
该注册研究分析2005至2021年间首次完全缓解期接受首次异基因造血细胞移植的成人核磷蛋白1突变初发急性髓系白血病患者共3275例,其中复杂核型72例。多因素分析显示复杂核型与较低总生存相关(HR 1.72,p=.009),在493例染色体异常亚组中复杂核型与微小/可测量残留病阳性均与复发风险增加和无白血病生存较差相关,而FLT3-ITD、单体核型或其他细胞遗传学异常无显著影响。
要点
- 复杂核型是核磷蛋白1突变急性髓系白血病首次完全缓解期移植后唯一与较差结局相关的细胞遗传学危险因素。
- 多因素分析中复杂核型与较低总生存相关(HR 1.72,p=.009)。
- 即使复杂核型亚组,仍有相当比例患者可获得长期移植后生存。
核心结论
- 在首次完全缓解期移植背景下,复杂核型是核磷蛋白1突变急性髓系白血病唯一与较差结局相关的细胞遗传学危险因素。
- 即使复杂核型亚组,仍有相当比例患者可获得长期移植后生存。
研究设计与样本
- 欧洲血液与骨髓移植学会急性白血病工作组的注册研究。
- 分析2005至2021年间首次完全缓解期接受首次异基因造血细胞移植的成人核磷蛋白1突变初发急性髓系白血病患者。
- 共识别3275例患者,2782例核型正常,493例有染色体异常(包括160例不良风险细胞遗传学),72例复杂核型,66例单体核型。
- 2377例(73%)患者FLT3-ITD阳性。
主要发现
- 单因素分析中仅FLT3-ITD、微小/可测量残留病阳性和复杂核型影响移植后结局,异常细胞遗传学不影响。
- 多因素分析中复杂核型与较低总生存相关(HR 1.72,p=.009)。
- 493例染色体异常亚组中2年无白血病生存和总生存分别约为61%和68%。
- 该亚组多因素分析中复杂核型与微小/可测量残留病阳性分别与复发风险增加相关(HR 1.7,p=.025;HR 1.99,p=.003)及无白血病生存较差相关(HR 1.62,p=.018;HR 1.64,p=.011),而FLT3-ITD、单体核型或其他细胞遗传学异常无显著影响。
- 复杂核型与较差总生存相关(HR 1.91,p=.002)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the 2022 European LeukemiaNet classification, patients with nucleophosmin 1 (NPM1)-mutated acute myeloid leukemia (AML) were classified in the adverse-risk category in the presence of high-risk cytogenetics (CG). Nonetheless, the impact of various CG aberrations on posttransplant outcomes remains to be unraveled. This registry study analyzed adult patients with NPM1-mutated de novo AML who underwent their first allogeneic hematopoietic cell transplantation in the first complete remission from 2005 to 2021. A total of 3275 patients were identified, 2782 had normal karyotype, 493 had chromosomal aberrations including 160 with adverse-risk CG, 72 patients had complex karyotype (CK), and 66 monosomal karyotype (MK). Overall, 2377 (73%) patients had FLT3-ITD. On univariate analysis, only FLT3-ITD, minimal/measurable residual disease (MRD) positivity and CK, but not abnormal CG, affected posttransplant outcomes. On multivariable analysis, CK was associated with lower overall survival (OS) (hazard ratio [HR] 1.72, p = .009). In the subgroup of 493 patients with aberrant CG, the 2-year leukemia-free survival (LFS) and OS were around 61% and 68%, respectively. On multivariable analysis for this subgroup, CK and MRD positivity were associated with increased risk of relapse (HR 1.7, p = .025; and 1.99, p = .003 respectively) and worse LFS (HR 1.62, p = .018; and 1.64, p = .011 respectively) while FLT3-ITD, MK, or other CG abnormalities had no significant effect. Importantly, CK negatively affected OS (HR 1.91, p = .002). In the first complete remission transplant setting, CK was found as the only cytogenetic risk factor for worse outcomes in NPM1-mutated AML. Nevertheless, even for this subgroup, a significant proportion of patients can achieve long-term posttransplant survival.
引用
- Moukalled N, Labopin M, Versluis J, et al. Complex karyotype but not other cytogenetic abnormalities is associated with worse posttransplant survival of patients with nucleophosmin 1-mutated acute myeloid leukemia: A study from the European Society for Blood and Marrow Transplantation Acute Leukemia Working Party. Am J Hematol. 2024. PMID: 38165072. doi:10.1002/ajh.27187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。